Vistagen Therapeutics (Vistagen Therapeutics) Book Value per Share : $4.56 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Vistagen Therapeutics Book Value per Share?

Vistagen Therapeutics's book value per share for the quarter that ended in Dec. 2023 was $4.56.

During the past 12 months, Vistagen Therapeutics's average Book Value Per Share Growth Rate was 52.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vistagen Therapeutics was 53.70% per year. The lowest was -1757.90% per year. And the median was 19.10% per year.

Vistagen Therapeutics's current price is $4.70. Its book value per share for the quarter that ended in Dec. 2023 was $4.56. Hence, today's PB Ratio of Vistagen Therapeutics is 1.03.

During the past 13 years, the highest P/B Ratio of Vistagen Therapeutics was 30.91. The lowest was 0.64. And the median was 3.57.

Vistagen Therapeutics Book Value per Share Historical Data

The historical data trend for Vistagen Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics Book Value per Share Chart

Vistagen Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Book Value per Share

Get a 7-Day Free Trial

4.98

-3.50

15.28

9.40

1.65

Vistagen Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Book Value per Share	Get a 7-Day Free Trial															3.00	1.65	0.87	2.97	4.56

Competitive Comparison of Vistagen Therapeutics's Book Value per Share

For the Biotechnology subindustry, Vistagen Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistagen Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's PB Ratio falls into.

Vistagen Therapeutics Book Value per Share Calculation

Vistagen Therapeutics's Book Value Per Share for the fiscal year that ended in Mar. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(12.08	-	0.00)	/	7.31
	=	1.65

Vistagen Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(123.29	-	0.00)	/	27.03
	=	4.56

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Vistagen Therapeutics (NAS:VTGN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Vistagen Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vistagen Therapeutics (Vistagen Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.

Executives

Joshua S. Prince	officer: Chief Operating Officer	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson	officer: CHIEF FINANCIAL OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin	director	343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler	officer: CHIEF LEGAL OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036